{"acquisitions":[],"changes":[],"country":"NL","description":"VarmX develops VMX-C001, a universal reversal agent that restores blood coagulation in patients on Factor Xa direct oral anticoagulants. It serves emergency-medicine teams treating severe bleeding and surgeons operating on anticoagulated patients. Its mechanism-agnostic restoration of clotting works across all FXa-DOACs, where the only approved competitor (Andexxa) targets only apixaban and rivaroxaban.","domain":"varmx.com","employees":null,"founded":2010,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":52.159475,"lng":4.490884,"location":"Leiden, Netherlands","multiples":[],"name":"VarmX","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":2700000,"connectionsAmong":[],"currency":"EUR","date":"2025-06-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"varmx-com-2025-06-01-grant","source":{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},"status":"attributed","type":"grant","url":null}],"slug":"varmx-com","sources":[{"fact":"round","publisher":"eu-grant","retrievedAt":"2026-05-08","status":"attributed","url":null},{"fact":"existence","publisher":"varmx.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://varmx.com"},{"fact":"description","publisher":"varmx.com","retrievedAt":"2026-05-08","status":"self-reported","url":"https://varmx.com"}],"stage":null,"stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Cloudflare","reCAPTCHA","Google Analytics","Google Tag Manager","Font Awesome","jQuery CDN","jQuery Migrate 3.4.1","imagesLoaded 5.0.0","Elementor 4.0.9","DoubleClick Floodlight","Cloudflare Bot Management","Contact Form 7 6.1.6"],"totalRaisedUsd":2700000,"traction":[],"updatedAt":"2026-05-08","valuations":[]}